$330.48
Value $300B
UNH and VMD stock compared: price, dividend, valuation and results, from SEC filings.
$330.48
Value $300B
$8.61
Value $332M
UnitedHealth (UNH) has a market value of $300B and Viemed Healthcare (VMD) $332M. Over the last year, with dividends, UNH moved +8.2% and VMD +36.5%. The P/E is 18.9 for UNH and 21.3 for VMD. Dividend yield: UNH 2.74%, VMD none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
UNH$300B
VMD$332M
UNH is 903 times VMD
Revenue, 12 months
UNH$450B
VMD$310M
UNH is 1,449 times VMD
Net income, 12 months
UNH$15.9B
VMD$16M
UNH is 1,017 times VMD
Operating margin
UNH5.3%
VMD7.8%
2.5 points apart
ROIC
UNH11.3%
VMD11.1%
0.2 points apart
P/E
UNH18.9
VMD21.3
VMD is 1.1 times UNH
Dividend yield
UNH2.7%
VMD0.0%
2.7 points apart
5-year return
UNH-19.5%
VMD+54.6%
74.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
UNH-19.5%
VMD+54.6%
| Period | UNHWith dividends | VMDWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +8.2%Price +5.4% | +36.5%Price +36.5% |
| 3 years since November 17, 2023 | -34.4%-13.1% a yearPrice -38.4% | +12.3%+3.9% a yearPrice +12.3% |
| 5 years since November 18, 2021 | -19.5%-4.2% a yearPrice -26.5% | +54.6%+9.1% a yearPrice +54.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
UNHUnitedHealthVMDViemed Healthcare
| Price | $330.48 | $8.61 |
|---|---|---|
| Market value | $300B | $332M |
| Enterprise value (EV) | $346B | $328M |
| P/E | 18.9 | 21.3 |
| P/E, 5-year median | 25.0 | 28.6 |
| P/B | 2.9 | 2.2 |
| EV/EBIT | 14.5 | 13.6 |
| Free cash flow yield | 7.6% | 6.4% |
| Revenue, 12 months | $450B | $310M |
|---|---|---|
| Net income, 12 months | $15.9B | $16M |
| Free cash flow, 12 months | $22.8B | $21M |
| Earnings per share, 12 months | $17.52 | $0.38 |
| Revenue growth, year on year | 11.8% | 20.5% |
| Revenue growth a year, past | +11.7%over 5 years | +15.5%over 5 years |
| EPS growth a year, past | -3.8%over 5 years | -13.9%over 5 years |
| Gross margin | 88.3% | 57.4% |
|---|---|---|
| Operating margin | 5.3% | 7.8% |
| Net margin | 3.5% | 5.0% |
| ROIC | 11.3% | 11.1% |
| ROE | 15.5% | 11.0% |
| Cash | $28.5B | $9.7M |
|---|---|---|
| Total debt | $74.3B | $9.3M |
| Net debt / EBITDA | 1.6 | -0.1 |
| Interest cover | 6.2× | – |
| Dividend yield | 2.7% | – |
|---|---|---|
| Dividend per share, 12 months | $9.06 | – |
| Dividend growth a year, past | +12.6%over 5 years | – |
| Buyback yield | 1.8% | 4.0% |
| Shareholder yield | 4.6% | 4.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($300B) is about 902.5 times Viemed Healthcare ($332M), at today's prices.
Since November 18, 2021, UNH's price moved -26.5% and VMD's +54.6%. With dividends: UNH -19.5% (-4.2% a year), VMD +54.6% (+9.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.74% for UnitedHealth and none for Viemed Healthcare. Over the last twelve months they paid $9.06 and – per share.
At today's price, the P/E is 18.9 for UNH and 21.3 for VMD. The median of the last five years was 25.0 and 28.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 3.5% for UnitedHealth and 5.0% for Viemed Healthcare, and the operating margin 5.3% and 7.8%. Revenue was $450B and $310M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.